Table 4.
Summary of adverse events (safety population).
| Preferred term | PEG IFN-α2b + SOC (N = 20) |
SOC (N = 20) |
|---|---|---|
| Adverse event | 11 (55.0%) | 8 (40.0%) |
| Breathlessness | 1 (5.0%) | 3 (15.0%) |
| Chest pain | 0 (0%) | 2 (10.0%) |
| Difficulty in breathing | 2 (10.0%) | 2 (10.0%) |
| Dryness in mouth | 1 (5.0%) | 1 (5.0%) |
| Headache | 8 (40.0%) | 4 (20.0%) |
| Hypoxia | 1 (5.0%) | 0 (0%) |
| Mouth dry | 0 (0%) | 2 (10.0%) |
| Nausea | 1 (5.0%) | 1 (5.0%) |
| Vomiting | 6 (30.0%) | 2 (10.0%) |
N = number of subjects in treatment group; PEG IFN-α2b = pegylated interferon alfa-2b; SOC = standard of care.